Home >> Marketplace Archives >> Companion diagnostic RPAs, 8/14

Companion diagnostic RPAs, 8/14

Print Friendly, PDF & Email

August 2014—Ventana Medical Systems launched three robust prototype assays for the detection of biomarkers PSMA (prostate specific membrane antigen), MDM2 (mouse double minute 2), and FGFR (fibroblast growth factor receptor 2). The new assays bring the company’s CAP/CLIA testing menu to almost 400—nearly 100 of which are RPA assays and the remainder are IVD-approved Ventana tests. Ventana CAP/CLIA RPAs adhere to the same rigorous, quality standards as the company’s commercial, FDA-approved and Class I IVD assays.

Ventana Medical Systems, 520-229-4617


Check Also

Ventana and Astellas join forces, 6/15

June 2015—Ventana Medical Systems has entered into a master collaboration agreement with Astellas Pharma, a research-and-development–driven pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.